Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Phase 1 clinical trial results for BT-600 demonstrate precise drug delivery to the colon with low systemic exposure, supporting clinical development plan

Company secures up to $16M funding from existing investors supported by BT-600 results and progress toward BioJet™ partnership